Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats

被引:30
作者
Fuchs, Robyn K. [1 ,2 ]
Phipps, Roger J. [4 ]
Burr, David B. [2 ,3 ]
机构
[1] Indiana Univ, Dept Phys Therapy, Indianapolis, IN 46202 USA
[2] Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA
[3] Indiana Univ, Sch Med, Dept Orthopaed Surg, Indianapolis, IN 46202 USA
[4] Procter & Gamble Pharmaceut, Mason, OH USA
关键词
bisphosphonates; ovariectomy; alendronate; risedronate; treatment withdrawal;
D O I
10.1359/JBMR.080501
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Alendronate (ALN) and risedronate (RIS) are bisphosphonates effective in reducing bone loss and fractures associated with postmenopausal osteoporosis. However, it is uncertain how long it takes bone turnover to be re-established after treatment withdrawal. and whether this differs between the two drugs. The objective of this study was to determine the time required to re-establish normal bone turnover after the discontinuation of ALN and RIS treatment in an animal model of estrogen-deficiency osteoporosis. Two hundred ten. 6-mo-old female Sprague-Dawley rats were ovariectomized and 6 wk later were randomized into baseline controls (n = 10) and four treatment groups (n = 50/group): vehicle-treated controls (CON; 0.3 ml sterile water). ALN (2.4 mu g/kg), low-dose RIS (RIS lows 1.2 mu g/kg). and high-close RIS (RIS high: 2.4 mu g/kg). Treatments were administered 3 times/wk by Subcutaneous injection. Baseline controls were killed at the initiation of treatments. Other groups were treated for 8 wk, and Subgroups (n = 10/ treatment group) were killed 0, 4, 8, 12 and 16 wk after treatment was withdrawn. Static and dynamic histological analyses were performed for cortical (tibial diaphysis) and trabecular (proximal tibia and L, vertebrae) bone. DXA and mechanical testing was performed on the L-5 vertebra. After 8 wk of treatment, trabecular bone turnover rates were significantly Suppressed in all drug-treated animals. Trabecular bone formation rate (BFR/BS) remained significantly low er than vehicle in bisphosphonate-treated animals through 12 wk. Sixteen weeks after treatment withdrawal, trabecular BFR/BS in the proximal tibia was re-established in animals treated with RIS but not in animals treated with ALN compared with controls. BMD of the fifth lumbar vertebra remained significantly higher than controls 16 wk after treatment withdrawal in ALN-treated animals but not in RIS-treated animals. Despite reductions in BMD and increases in bone turnover, ultimate force of the fifth lumbar vertebra remained significantly higher in all drug-treated animals through 16 wk after withdrawal.
引用
收藏
页码:1689 / 1697
页数:9
相关论文
共 55 条
[1]
Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters [J].
Arlot, M ;
Meunier, PJ ;
Boivin, G ;
Haddock, L ;
Tamayo, J ;
Correa-Rotter, R ;
Jasqui, S ;
Donley, DW ;
Dalsky, GP ;
San Martin, J ;
Eriksen, EF .
JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (07) :1244-1253
[2]
Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal [J].
Bagger, YZ ;
Tankó, LB ;
Alexandersen, P ;
Ravn, P ;
Christiansen, C .
BONE, 2003, 33 (03) :301-307
[3]
Bilezikian J P, 2005, J Endocrinol Invest, V28, P41
[4]
Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial [J].
Black, Dennis M. ;
Schwartz, Ann V. ;
Ensrud, Kristine E. ;
Cauley, Jane A. ;
Levis, Silvina ;
Quandt, Sara A. ;
Satterfield, Suzanne ;
Wallace, Robert B. ;
Bauer, Douglas C. ;
Palermo, Lisa ;
Wehren, Lois E. ;
Lombardi, Antonio ;
Santora, Arthur C. ;
Cummings, Steven R. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (24) :2927-2938
[5]
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis [J].
Black, DM ;
Greenspan, SL ;
Ensrud, KE ;
Palermo, L ;
McGowan, JA ;
Lang, TF ;
Garnero, P ;
Bouxsein, ML ;
Bilezikian, JP ;
Rosen, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (13) :1207-1215
[6]
Ten years' experience with alendronate for osteoporosis in postmenopausal women [J].
Bone, HG ;
Hosking, D ;
Devogelaer, J ;
Tucci, JR ;
Emkey, RD ;
Tonino, RP ;
Rodriguez-Portales, JA ;
Downs, RW ;
Gupta, J ;
Santora, AC ;
Liberman, UA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (12) :1189-1199
[7]
Human osteoclast formation and activity in vitro: Effects of alendronate [J].
Breuil, V ;
Cosman, F ;
Stein, L ;
Horbert, W ;
Nieves, J ;
Shen, V ;
Lindsay, R ;
Dempster, DW .
JOURNAL OF BONE AND MINERAL RESEARCH, 1998, 13 (11) :1721-1729
[8]
Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats [J].
Cao, YP ;
Mori, S ;
Mashiba, T ;
Westmore, MS ;
Ma, L ;
Sato, M ;
Akiyama, T ;
Shi, LP ;
Komatsubara, S ;
Miyamoto, K ;
Norimatsu, H .
JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 (12) :2237-2246
[9]
Developments in the pharmacotherapeutic management of osteoporosis [J].
Close, Pierre ;
Neuprez, Audrey ;
Reginster, Jean-Yves .
EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (12) :1603-1615
[10]
Meta-analysis of alendronate for the treatment of postmenopausal women [J].
Cranney, A ;
Wells, G ;
Willan, A ;
Griffith, L ;
Zytaruk, N ;
Robinson, V ;
Black, D ;
Adachi, J ;
Shea, B ;
Tugwell, P ;
Guyatt, G .
ENDOCRINE REVIEWS, 2002, 23 (04) :508-516